1. Home
  2. TOPS vs SHPH Comparison

TOPS vs SHPH Comparison

Compare TOPS & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TOP Ships Inc.

TOPS

TOP Ships Inc.

HOLD

Current Price

$0.30

Market Cap

2.2M

ML Signal

HOLD

Logo Shuttle Pharmaceuticals Holdings Inc.

SHPH

Shuttle Pharmaceuticals Holdings Inc.

N/A

Current Price

$5.43

Market Cap

2.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TOPS
SHPH
Founded
2000
2012
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.1M
IPO Year
2004
2022

Fundamental Metrics

Financial Performance
Metric
TOPS
SHPH
Price
$0.30
$5.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 594.9K
37.6K
Earning Date
09-16-2026
11-12-2026
Dividend Yield
★ 287.62%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.14
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.38
52 Week High
$7.40
$8.88

Technical Indicators

Market Signals
Indicator
TOPS
SHPH
Relative Strength Index (RSI) 22.20 61.63
Support Level N/A $2.92
Resistance Level $1.29 $5.95
Average True Range (ATR) 0.04 0.44
MACD -0.01 -0.02
Stochastic Oscillator 10.24 83.82

Price Performance

Historical Comparison
TOPS
SHPH

About TOPS TOP Ships Inc.

TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco-tanker vessels, focusing on the transportation of crude oil, petroleum products (both clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements. The company operates in two reportable segments: (i) the tanker segment and (ii) the megayacht segment.

About SHPH Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.

Share on Social Networks: